Focused On-demand Library for Excitatory amino acid transporter 3

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

P43005

UPID:

EAA3_HUMAN

Alternative names:

Excitatory amino-acid carrier 1; Neuronal and epithelial glutamate transporter; Sodium-dependent glutamate/aspartate transporter 3; Solute carrier family 1 member 1

Alternative UPACC:

P43005; O75587; Q5VZ24; Q8N199; Q9UEW2

Background:

Excitatory amino acid transporter 3, also known as EAAT3, plays a pivotal role in the central nervous system. It is a sodium-dependent, high-affinity transporter responsible for the uptake of neurotransmitters like L-glutamate, L-aspartate, and D-aspartate. This protein is crucial for maintaining synaptic strength and plasticity by ensuring the rapid removal of glutamate from the synaptic cleft, thus preventing excitotoxicity.

Therapeutic significance:

EAAT3's involvement in diseases such as Dicarboxylic aminoaciduria and Schizophrenia 18 highlights its potential as a therapeutic target. The protein's role in glutamate reabsorption and protection against oxidative stress through glutathione biosynthesis suggests that modulating its activity could offer new avenues for treating neurological disorders and enhancing brain health.